by Webdesign Squad | Jul 23, 2021 | News
Carvolix published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency. • Preclinical in vivo results published in The Annals of Thoracic...
by Webdesign Squad | Jul 23, 2021 | News
Carvolix announces the approval of its Registration Document by the French Financial Markets Authority (Autorité des marchés financiers – AMF) as part of its proposed IPO on the Euronext Paris regulated market Carvolix, a French medtech specialising in the...
by Webdesign Squad | Mar 5, 2021 | News
The Private Placement Financing was taken out for gross proceeds of €10.3 million, €8 million via convertible bonds (of which €4 million were received in December 2019). Carvolix has been granted two “PGE” (government-backed) loans for a total of €2.2 million from the...
by Webdesign Squad | Mar 5, 2021 | News
Epygon is the first transcatheter mitral valve designed to restore the physiological blood flow vortex and treat left ventricle disease, in particular in so-called “functional” patients. No mitral valve prosthesis currently on the market or in development was designed...
by Webdesign Squad | Mar 5, 2021 | News
KALIOS is the first fully adjustable mitral valve repair ring, designated for the percutaneous treatment of both residual and recurrent Mitral Regurgitation (MR). First patient implanted in Vienna General Hospital (AKH) Obtention of regulatory approval to start...
by Webdesign Squad | Mar 5, 2021 | News
Michel Finance is appointed CEO.Executive team is strengthened with the appointment of:Daniele Zanotti (the former CEO) as Chief Technology and Innovation Officer leading technology developments and the execution of programs,Professor François Laborde as Chief...
Recent Comments